Acasti Pharma (NASDAQ:ACST – Free Report) had its target price increased by Craig Hallum from $6.00 to $8.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.
Acasti Pharma Price Performance
Shares of Acasti Pharma stock opened at $3.12 on Thursday. The business’s fifty day moving average price is $2.59 and its two-hundred day moving average price is $2.90. The company has a market capitalization of $29.32 million, a P/E ratio of -2.17 and a beta of 1.51. Acasti Pharma has a 1-year low of $1.98 and a 1-year high of $3.59.
Acasti Pharma (NASDAQ:ACST – Get Free Report) last announced its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. On average, research analysts expect that Acasti Pharma will post -1.14 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Acasti Pharma
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Articles
- Five stocks we like better than Acasti Pharma
- What Are Dividend Challengers?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Are Penny Stocks a Good Fit for Your Portfolio?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.